Search clinical trials for: atazanavir/tenofovir/emtricitabine

Total 1202 results

First Affiliated Hospital Xi'an Jiaotong University

Unknown

Study of Antiretroviral Therapy to Prevent HBV Intrauterine Infection

Hepatitis B, Chronic

China
Giovanni Di Perri
University of Turin, Italy; University of Milan

Terminated

Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir (RALBAT)

HIV Infection | Osteopenia

Italy
Kenneth H. Mayer, MD
Bristol-Myers Squibb; Gilead Sciences; Abbott

Terminated

Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV (BMS PEP)

HIV

United States
Juan A. Arnaiz

Completed

Metabolic Effects of Atazanavir/Ritonavir Versus Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine in naïve HIV-1 Infected Patients

HIV-1

Spain
Community Research Initiative of New England
Bristol-Myers Squibb; Merck Sharp & Dohme LLC

Completed

BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated. (BATAR)

HIV

United States
Bristol-Myers Squibb

Completed

Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access

HIV

Argentina, France, Taiwan, Thailand, United States, Chile, Spain, Dominican Republic, Guatemala, Peru, Puerto Rico, Singapore, Russian Federation, Italy, Mexico, Colombia, South Africa, Brazil, Hungary, Malaysia, Portugal, Canada, I... and more
International Medical Center of Japan
Ministry of Health, Labour and Welfare, Japan

Completed

Comparison of Epzicom and Truvada for the Initial Once Daily HIV Treatment

HIV Infections

Japan
The University of Texas Health Science Center,...
Merck Sharp & Dohme LLC

Completed

Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients (RAN)

HIV Infections

United States
University of Alabama at Birmingham
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in Healthy Women

Healthy

United States
Juan A. Arnaiz

Completed

Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl (ADVANZ-3)

HIV Infections

Spain
Bristol-Myers Squibb

Terminated

Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC

HIV
French National Agency for Research on AIDS and...
Bristol-Myers Squibb; Gilead Sciences

Completed

Measure of Pharmacokinetic Parameters and Adherence With MEMS in Naive HIV Infected Patients Treated With Reyataz Once Daily Combined With Norvir and Truvada (ANRS134COPHAR3)

HIV Infections

France
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters

HIV Infection

United States
Eastern Virginia Medical School
Gilead Sciences; United States Agency for International Development (USAID); FHI... and other collaborators

Active, not recruiting

Project Engage: Oral PrEP Acceptability

Adherence, Medication | Acceptability of Health Care

South Africa, Zimbabwe
Tibotec, Inc
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment

HIV

United States
University of Alabama at Birmingham
National Institute of Allergy and Infectious Diseases (NIAID)

Withdrawn

Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in HIV-Infected Women

HIV Infected

United States
Gilead Sciences

Completed

Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients

HIV Infections

United States
Kirby Institute
The University of New South Wales

Completed

ALTAIR - Alternative Antiretroviral Strategies : a Comparison of Three Initial Regimens

Human Immunodeficiency Virus (HIV)
AIDS Clinical Trials Group
Bristol-Myers Squibb; National Institute of Allergy and Infectious Diseases... and other collaborators

Completed

Comparative Study of Three NNRTI-Sparing HAART Regimens

HIV Infection

United States, Puerto Rico
Asan Medical Center
Bristol-Myers Squibb

Unknown

Two Clinical Trials to Evaluate Pharmacokinetics of Unboosted and Boosted Atazanavir Used Alone or Co-administered With Tenofovir DF in Healthy Korean and Caucasian Male Volunteers

Atazanavir

Korea, Republic of
National Institute of Allergy and Infectious Diseases...
Microbicide Trials Network

Completed

Bone Mineral Density Substudy - An Ancillary Study to MTN-003

HIV Infections

Zimbabwe, Uganda
University Health Network, Toronto
Gilead Sciences; University of Modena and Reggio Emilia; San Raffaele University... and other collaborators

Completed

Bone Health in Aging HIV Infected Women (BEING)

Menopause | HIV | Osteoporosis

Canada, Italy
University of North Carolina, Chapel Hill
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among 15 to 17 Year Old Young Men Who Have Sex With Men (YMSM)

HIV Infection

United States
National Institute of Allergy and Infectious Diseases...
Microbicide Trials Network

Completed

Safety and Effectiveness of TFV 1% Gel, TDF Tablets, and FTC/TDF Tablets in Preventing HIV in Women

HIV Infections

South Africa, Uganda, Zimbabwe
University of California, San Diego
Gilead Sciences; University at Buffalo

Completed

Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals

HIV

United States
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

Safety of Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine/TDF in HIV Infected Pregnant Women and Their Infants

HIV Infections

United States, Puerto Rico
University of North Carolina, Chapel Hill
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population

Human Immunodeficiency Virus

United States
Vancouver Infectious Diseases Centre

Unknown

Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Marginalized Populations Who Are Virologically Suppressed

Drug Use | Human Immunodeficiency Virus I Infection

Canada
Valley AIDS Council
Gilead Sciences

Not yet recruiting

Advanced HIV: Outcomes for Rapid ART (AHORA)

HIV-1-infection
University of Nebraska
Gilead Sciences

Completed

Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE (BASE)

HIV-1-infection

United States
Fenway Community Health

Completed

Biktarvy for Non-Occupational Post-Exposure Prophylaxis (nPEP)

HIV Prevention

United States
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults

HIV Infections

United States, Puerto Rico
Bristol-Myers Squibb

Completed

BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada

HIV Infections

Chile, Portugal, Spain, Italy, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Colombia, Costa Rica, Dominican Republic, France, Germany, Guatemala, Hong Kong, Indonesia, Mexico, Netherlands, Panama, Peru, Puerto... and more
University of California, San Diego

Active, not recruiting

Emtricitabine/Tenofovir Alafenamide Switch Study for Transgender Individuals for HIV Pre-exposure Prophylaxis (TAF4TRANS)

Hiv | Hormone Therapy

United States
National Taiwan University Hospital
Mackay Memorial Hospital; Kaohsiung Medical University Chung-Ho Memorial Hospital and other collaborators

Unknown

Same-day Antiretroviral Therapy With BIC/F/TAF

HIV Infections

Taiwan
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)

HIV Infections | Infection, Human Immunodeficiency Virus

United States, France, Spain, United Kingdom, Canada, Thailand, Italy, Portugal, Russian Federation, Mexico, Argentina, South Africa, Puerto Rico
Bristol-Myers Squibb

Completed

Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients (SPARTAN)

HIV, Combination Therapy

France, Germany, Spain, United States, Italy, Poland, United Kingdom
Janssen Sciences Ireland UC

Completed

Relative Bioavailability and Food Effect for Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination

Healthy

Belgium
Merck Sharp & Dohme LLC

Completed

Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024) (Impower-024)

HIV Preexposure Prophylaxis

United States, Brazil, France, Japan, South Africa, Thailand, Peru
Bristol-Myers Squibb
Merck Sharp & Dohme LLC

Terminated

Phase IIB Pilot of Atazanavir + Raltegravir (SPARTAN)

HIV

Argentina, United States, France
Merck Sharp & Dohme LLC

Active, not recruiting

Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022) (Impower-022)

Prophylaxis | Human Immunodeficiency Virus Type 1 | HIV-I

United States, South Africa, Uganda
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Recruiting

Doravirine for Persons With Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide

HIV Infections

United States
University of Maryland, Baltimore
Gilead Sciences

Completed

B/F/TAF Switch Study for HIV-HBV Coinfection (BEST-HBV)

Hepatitis B | HIV-1-infection

United States
HQ Toronto
Gilead Sciences

Active, not recruiting

Express Testing and Same-day Initiation of PrEP Study (Express-PrEP)

HIV Prevention

Canada
Quest Clinical Research
Gilead Sciences

Completed

Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine

HIV-1-infection

United States
University of KwaZulu
Medical Research Council, South Africa; Centre for the AIDS Programme of Research...

Completed

Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women (PrEP)

HIV-1-infection

South Africa
University of Manitoba
World Health Organization; DMSC; Ashodaya Samithi

Completed

Demonstrating Safety and Effective Delivery of Daily Oral Pre-exposure Prophylaxis (PrEP) for Sex Workers in India (PrEP-India)

HIV Infection

India
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants (VESTED)

HIV Infections

United States, South Africa, Thailand, Botswana, Brazil, Tanzania, Zimbabwe, India, Uganda
Thomas Jefferson University
University of Illinois at Chicago; University of California, San Francisco; Nova... and other collaborators

Completed

The Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment Experienced Patients

HIV/AIDS

United States
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects (Study P04875)

HIV Infections

Search clinical trials for: atazanavir/tenofovir/emtricitabine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations